Comparative Pharmacology
Head-to-head clinical analysis: PIMOZIDE versus THIOTHIXENE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PIMOZIDE versus THIOTHIXENE HYDROCHLORIDE.
PIMOZIDE vs THIOTHIXENE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Blocks dopamine D2, D3, and D4 receptors; also 5-HT2A, α1-adrenergic, and H1 receptors.
Thiothixene hydrochloride is a typical antipsychotic that blocks postsynaptic dopamine D2 receptors in the central nervous system (CNS), particularly in the mesolimbic and mesocortical pathways. It also has alpha-adrenergic blocking activity and weak anticholinergic effects.
1-10 mg orally once daily; maximum 10 mg/day.
Initial: 2-5 mg orally 3 times daily; maintenance: 15-30 mg orally per day in divided doses; maximum: 60 mg orally per day.
None Documented
None Documented
Terminal elimination half-life is approximately 50-60 hours in adults; may be prolonged in elderly or hepatic impairment.
Clinical Note
moderatePimozide + Levofloxacin
"Pimozide may increase the QTc-prolonging activities of Levofloxacin."
Clinical Note
moderatePimozide + Norfloxacin
"Pimozide may increase the QTc-prolonging activities of Norfloxacin."
Clinical Note
moderatePimozide + Gemifloxacin
"Pimozide may increase the QTc-prolonging activities of Gemifloxacin."
Clinical Note
moderatePimozide + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Pimozide is combined with Fluticasone propionate."
Terminal elimination half-life: 34 hours (range 25–50 hrs) in adults; clinical context: allows once-daily dosing.
Primarily hepatic metabolism; renal excretion of metabolites accounts for approximately 70-90% of eliminated drug; fecal excretion ~10-30%.
Renal: primarily as metabolites, <1% unchanged; fecal: minor; biliary: some metabolites excreted in bile.
Category A/B
Category C
Typical Antipsychotic
Typical Antipsychotic